• Target disease: Chagas
  • Main Partners (since project start): AbbVie, USA; Bioaster, France; Centre for Drug Candidate Optimisation (CDCO), Monash University, Australia; Epichem, Australia; Eurofins CEREP, France; Griffith Institute for Drug Discovery, Griffith University, Australia; London School of Hygiene and Tropical Medicine, UK; WuXi App Tech, China.
  • Project start: 2017
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland.


Overall Objective:

  • Optimize leads issued from the hit-to-lead 205 series, and identify pre-clinical candidates with the potential to fulfill the target product profile for Chagas disease



Following curative activity in vivo observed for several lead compounds of the 205 series, work in 2017 concentrated on better understanding the necessary parameters for obtaining cure in animals, in particular by testing different regimens and doses while exploring further optimization. Further characterization of this series is ongoing, and compounds are being profiled for candidate nomination. More than 400 compounds have been synthesized by this programme to date.

Last update: August 2018